PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 9, 2025The Journal of Urology2 citationsOpen Access

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial

View Full Paper
NSNeal D. ShoreMGMartin GleaveUGUgo De Giorgi

Key Points

  • To evaluate the efficacy of enzalutamide combined with leuprolide in treating high-risk biochemically recurrent prostate cancer.
  • Participants received enzalutamide alongside leuprolide treatment.
  • Secondary endpoints were assessed from the EMBARK trial.
  • The study focused on biochemical recurrence in prostate cancer patients.
  • Combination therapy improved outcomes related to biochemical recurrence.
  • Findings suggest potential benefits for high-risk patients receiving this treatment.

Abstract

Nct02319837.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Shore et al. (2025) studied this question.

synapsesocial.com/papers/69401d732d562116f28f9539https://doi.org/10.1097/ju.0000000000004890
Ask AI
Helpful
Bookmark
Share
View Full Paper